Holen Sie sich die Stockscreener-App
91.83
0.54%
-0.50
Handel nachbörslich:
91.50
-0.33
-0.36%
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season - TradingView
BioNTech SE (0A3M) to Announce Q2 2026 Financial Results and Host Investor Call on August 4 - Kalkine Media
Biontech Se Sponsored Adr (BNTX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Arbutus and Genevant file patent lawsuits against Pfizer, BioNTech - Investing.com
BioNTech Burns Through Cash as It Prepares for a Pivotal Wave of Cancer Data () - aktiencheck.de
BioNTech's Balancing Act: Plant Closures, Founders' Exit, and a Bet on Six Key Cancer Studies - aktiencheck.de
BioNTech’s Triple Transformation: Shuttering Plants, Losing Founders, and Banking on 15 Cancer Trials - aktiencheck.de
SK Hynix readies U.S. market debut as NATO strains and Gulf shipping risks unsettle investors - Traders Union
Cathie Wood Scoops Up SpaceX Shares Again as Stock Dips, Ark Keeps Offloading AMD Shares - Sahm
Cathie Wood’s ARK sells BioNTech and buys SpaceX stock - Investing.com
10 Newly Overvalued Stocks this Week - Morningstar
BioNTech’s Factory Sell-Off and a Founder’s Spin-Off: Two Bets That Could Reshape the Stock - aktiencheck.de
PTC Therapeutics (PTCT) moves 7.2% higher: Will this strength last? - MSN
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week? - TradingView
European ADRs Jumped As Biotech Led The Pack - Finimize
BioNTech SE ADR (BNTX) News Today: Latest Market and Industry Updates - Traders Union
BioNTech stock trades down as founders leave the company, raising transition concerns - Traders Union
Comirnaty Omicron-adapted formulation from BioNTech SEupdated mRNA shot for the 2024-25 season - ad-hoc-news.de
Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech SE Sponsored ADR Actuals & Estimates (NASDAQ:BNTX) - TradingView
Price to sales forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Enterprise value to EBIT forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech’s Oncology Transformation Hinges on Dense Second-Half Data Flow () - aktiencheck.de
BioNTech (BNTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Price to earnings forward of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
Ubiquiti Upgraded, Reddit Downgraded: Updated Rankings on Top Blue-Chip Stocks - Yahoo Finance
BioNTech's €16.8 Billion Cash Hoard Is the Prize as Moderna Circles Factories and Spin-Off Looms - aktiencheck.de
Why BioNTech’s BNT316/ ONC-392 could quietly change lung cancer care - Ad-hoc-news.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
BioNTech Faces Shareholder Revolt Over Spin-Off Even as It Prepares First US Cancer Filing - aktiencheck.de
BioNTech Slashes 1,800 Jobs and Kicks Off $1 Billion Buyback in Oncology Push () - aktiencheck.de
Founders Exit and 1,860 Jobs Cut: Inside BioNTech’s Radical Pivot as It Launches a $1B Buyback and Awaits Six Cancer Data Readouts () - aktiencheck.de
BioNTech SE Stock (US09075V1026): Buyback And Oncology Pipeline Keep Shares In Focus - Ad-hoc-news.de
BioNTech Stands at a Pivotal Juncture as First FDA Filing Approaches and Pipeline Data Piles Up - aktiencheck.de
Moderna Says New COVID Vax Doesn't Infringe BioNTech IP - Law360
BioNTech Has $16.8 Billion in Cash, a $1 Billion Buyback, and Promising Cancer Data — So Why Is the Stock Stuck? - aktiencheck.de
BioNTech: When Pipeline Progress Meets a Market That Demands Revenue () - aktiencheck.de
Comirnaty COVID-19 Vaccine: What Matters Now for US Patients - AD HOC NEWS
Bristol-Myers Upgraded, Broadcom Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Pipeline Pivot Meets a Market That Won’t Look Up () - aktiencheck.de
BioNTech Stock: A Week of Crosscurrents Where Macro and a Medical Congress Collide () - aktiencheck.de
BioNTech Faces Twin Headwinds: Analyst Divergence and German Health Overhaul () - aktiencheck.de
Bernstein reiterates BioNTech stock rating on pumitamig risks - Investing.com
BioNTech's Oncology Momentum Clashes With Berlin's Health-Cost Crackdown () - aktiencheck.de
BioNTech’s Costly Pivot: Cancer Pipeline Promises Meet Political and Financial Realities () - aktiencheck.de
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
BioNTech's ASCO Data Showcase Two Late-Stage Hopes Amid Cost Cuts and a $1 Billion Buyback - aktiencheck.de
BNTX Technical Analysis | Trend, Signals & Chart Patterns | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech Races Toward First Oncology Approval as ASCO Data Bolsters Pipeline Credibility - aktiencheck.de
BNTX Stock Quote Price and Forecast - CNN
Pumitamig’s 72.7% Response at Reduced Dose Reshapes BioNTech’s Oncology Ambitions () - aktiencheck.de
BioNTech’s ASCO Data Blitz Fails to Close Analyst Split as First FDA Filing Looms () - aktiencheck.de
BioNTech Juggles Vaccine Tweaks and Cancer Milestones as Investors Look Beyond COVID - aktiencheck.de
A 4,000% gain is not enough? SanDisk, BioNTech, and Standard Uranium - news.financial
BioNTech Shows Its Hand at ASCO: A Pipeline in Full Bloom and a Radical Cost Overhaul () - aktiencheck.de
BNTXBioNTech SE ADR Dividends - Finviz
BioNTech upgraded to “buy” at UBS as next-gen cancer drugs de-risk - Investing.com
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
BioNTech Grapples With Labor Strife and Analyst Skepticism as Stock Languishes () - aktiencheck.de
1.36%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):